Delving into the Latest Updates on GX-02 with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Brain metastasesNon-Small Cell Lung Cancer

Originator Organization

Genexine, Inc.

Active Organization-

Inactive Organization

Genexine, Inc.

License Organization-

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

Three new lanostane triterpenoids (1-3) along with two new amides fatty compounds (4-5) were isolated from the ethyl acetate extract of a culture of the endophytic fungus Alternaria sp. gx-2. Their structures were identified by 1D and 2D NMR spectral data and HRESIMS. Compounds 1-12 were evaluated for their anti-inflammatory and tyrosinase inhibition activities. The isolated compounds did not show inhibitory activities at a concentration of 100 μM against tyrosinase, while under the concentration of 10 μM, the release of lactate dehydrogenase (LDH) inhibition rate of compound 1 was 54.45%, indicating that compound 1 had moderate anti-inflammatory activity on the activation of NLRP3 inflammasome.

100 Deals associated with GX-02

Login to view more data